NMRA Long Call Strategy

NMRA (Neumora Therapeutics, Inc. Common Stock), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021.

NMRA (Neumora Therapeutics, Inc. Common Stock) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $303.9M, a beta of 2.76 versus the broader market, a 52-week range of 0.716-3.65, average daily share volume of 2.1M, a public-listing history dating back to 2023, approximately 110 full-time employees. These structural characteristics shape how NMRA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.76 indicates NMRA has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on NMRA?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current NMRA snapshot

As of June 30, 2026, spot at $1.69, ATM IV 101.10%, IV rank 19.94%, expected move 28.98%. The long call on NMRA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this long call structure on NMRA specifically: NMRA IV at 101.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a NMRA long call, with a market-implied 1-standard-deviation move of approximately 28.98% (roughly $0.49 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NMRA expiries trade a higher absolute premium for lower per-day decay. Position sizing on NMRA should anchor to the underlying notional of $1.69 per share and to the trader's directional view on NMRA stock.

NMRA long call setup

The NMRA long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NMRA near $1.69, the first option leg uses a $1.69 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NMRA chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NMRA shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$1.69N/A

NMRA long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

NMRA long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on NMRA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on NMRA

Long calls on NMRA express a bullish thesis with defined risk; traders use them ahead of NMRA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

NMRA thesis for this long call

The market-implied 1-standard-deviation range for NMRA extends from approximately $1.20 on the downside to $2.18 on the upside. A NMRA long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current NMRA IV rank near 19.94% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NMRA at 101.10%. As a Healthcare name, NMRA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NMRA-specific events.

NMRA long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NMRA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NMRA alongside the broader basket even when NMRA-specific fundamentals are unchanged. Long-premium structures like a long call on NMRA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current NMRA chain quotes before placing a trade.

Frequently asked questions

What is a long call on NMRA?
A long call on NMRA is the long call strategy applied to NMRA (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With NMRA stock trading near $1.69, the strikes shown on this page are snapped to the nearest listed NMRA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are NMRA long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the NMRA long call priced from the end-of-day chain at a 30-day expiry (ATM IV 101.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a NMRA long call?
The breakeven for the NMRA long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NMRA market-implied 1-standard-deviation expected move is approximately 28.98%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on NMRA?
Long calls on NMRA express a bullish thesis with defined risk; traders use them ahead of NMRA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current NMRA implied volatility affect this long call?
NMRA ATM IV is at 101.10% with IV rank near 19.94%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related NMRA analysis